ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,814.40
-0.85%
S&P ASX All Technology
3,045.20
-2.07%
Brent Oil
83.76
0.00%
US Dollar vs AUD
1.49165
0.00%
Bitcoin
67,110.12
0.25%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Autolus Therapeutics PLC (AUTL)

  7. Autolus Therapeutics PLC (AUTL) News

AUTL

Autolus Therapeutics (AUTL)

Autolus Therapeutics PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AUTL
DateTimeSourceHeadlineSymbolCompany
18/05/202406:39Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AUTLAutolus Therapeutics PLC
17/05/202422:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
17/05/202421:00GlobeNewswire Inc.Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
15/05/202400:00GlobeNewswire Inc.Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) CongressNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202423:33Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202421:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202421:00GlobeNewswire Inc.Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference CallNASDAQ:AUTLAutolus Therapeutics PLC
25/04/202400:00GlobeNewswire Inc.Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCONASDAQ:AUTLAutolus Therapeutics PLC
23/04/202421:00GlobeNewswire Inc.Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024NASDAQ:AUTLAutolus Therapeutics PLC
02/04/202422:00GlobeNewswire Inc.Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALLNASDAQ:AUTLAutolus Therapeutics PLC
01/04/202422:00GlobeNewswire Inc.Autolus Therapeutics Announces Changes to its Board of DirectorsNASDAQ:AUTLAutolus Therapeutics PLC
14/03/202422:00GlobeNewswire Inc.Autolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
12/03/202422:00GlobeNewswire Inc.Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing siteNASDAQ:AUTLAutolus Therapeutics PLC
11/03/202422:00GlobeNewswire Inc.Autolus Therapeutics announces publication in Blood Cancer JournalNASDAQ:AUTLAutolus Therapeutics PLC
29/02/202423:00GlobeNewswire Inc.Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024NASDAQ:AUTLAutolus Therapeutics PLC
24/02/202409:28Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AUTLAutolus Therapeutics PLC
22/02/202423:00GlobeNewswire Inc.Autolus Therapeutics announces publication in Nature Communications NASDAQ:AUTLAutolus Therapeutics PLC
22/02/202409:01Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AUTLAutolus Therapeutics PLC
15/02/202400:37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
10/02/202409:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AUTLAutolus Therapeutics PLC
09/02/202408:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
08/02/202423:00GlobeNewswire Inc.Autolus Announces Pricing of Underwritten OfferingNASDAQ:AUTLAutolus Therapeutics PLC
08/02/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
08/02/202421:45GlobeNewswire Inc.BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs  NASDAQ:AUTLAutolus Therapeutics PLC
08/02/202414:00Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:AUTLAutolus Therapeutics PLC
01/02/202408:10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
27/01/202405:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
23/01/202423:00GlobeNewswire Inc.Autolus Therapeutics announces publication in ACS Chemical BiologyNASDAQ:AUTLAutolus Therapeutics PLC
22/01/202423:54Dow Jones NewsAutolus Therapeutics Gets BLA Acceptance for Obecabtagene AutoleucelNASDAQ:AUTLAutolus Therapeutics PLC
22/01/202423:00GlobeNewswire Inc.Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)NASDAQ:AUTLAutolus Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:AUTL

Your Recent History

EU
XS1400651706
Essence VI Bv 0.5% until...
BOV
WABC34R
Western Alliance Bancorp
LSE
AN39
Citi Fun 24
BIT
A2A
A2A
USOTC
NRSAF
Norse Atlantic ASA (QX)
LSE
3HSB
3x Hsbc
BIT
F16801
Vontobel Financial Produ...
LSE
DZ35
Citi Fun 25
LSE
FE10
Citi Fun 24
BIT
ESREUA
Ubs Etf Msci Europe & Mi...
CRTO
ETHWUSD
Ethereum PoW
LSE
40LQ
Utd Wtr.1.5802%
KOSPI
089590
Jejuair
LSE
FE78
Citi Holding.26
EU
P633S
P633S
LSE
FL44
Citi Fun 32
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved